GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » EV-to-EBITDA

Aurobindo Pharma (NSE:AUROPHARMA) EV-to-EBITDA : 12.01 (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aurobindo Pharma's enterprise value is ₹676,844 Mil. Aurobindo Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹56,374 Mil. Therefore, Aurobindo Pharma's EV-to-EBITDA for today is 12.01.

The historical rank and industry rank for Aurobindo Pharma's EV-to-EBITDA or its related term are showing as below:

NSE:AUROPHARMA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.45   Med: 10.39   Max: 19.68
Current: 12.01

During the past 13 years, the highest EV-to-EBITDA of Aurobindo Pharma was 19.68. The lowest was 4.45. And the median was 10.39.

NSE:AUROPHARMA's EV-to-EBITDA is ranked better than
58.72% of 705 companies
in the Drug Manufacturers industry
Industry Median: 14.58 vs NSE:AUROPHARMA: 12.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Aurobindo Pharma's stock price is ₹1168.60. Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹47.250. Therefore, Aurobindo Pharma's PE Ratio for today is 24.73.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Aurobindo Pharma EV-to-EBITDA Historical Data

The historical data trend for Aurobindo Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma EV-to-EBITDA Chart

Aurobindo Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.04 5.70 6.07 8.35 7.38

Aurobindo Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.92 7.38 10.13 10.72 11.27

Competitive Comparison of Aurobindo Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's EV-to-EBITDA falls into.



Aurobindo Pharma EV-to-EBITDA Calculation

Aurobindo Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=676844.458/56374
=12.01

Aurobindo Pharma's current Enterprise Value is ₹676,844 Mil.
Aurobindo Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹56,374 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (NSE:AUROPHARMA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aurobindo Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1168.60/47.250
=24.73

Aurobindo Pharma's share price for today is ₹1168.60.
Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹47.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Aurobindo Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines